Artiva Biotherapeutics, Inc. (ARTV) vs Relmada Therapeutics, Inc. (RLMD)

A side-by-side comparison of Artiva Biotherapeutics, Inc. and Relmada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Artiva Biotherapeutics, Inc. logo
ARTV
Artiva Biotherapeutics, Inc.
$354M
$7.24HealthcareDelayed quote: Oct 6, 2026, 1:04 PM EDT
Relmada Therapeutics, Inc. logo
RLMD
Relmada Therapeutics, Inc.
$349M
$3.33HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

Total return — ARTV vs RLMD

growth of $100 · dividends reinvested · last 2y
ARTV -40.6% (-22.9%/yr)RLMD +234.6% (+82.9%/yr)RLMD compounded faster over this window
Log scale — wide-divergence pair
101001kStart $10020252026$59$335
ARTV RLMD

ARTV vs RLMD: by the numbers

  • •ARTV is the larger company ($354M vs $349M market cap).

Metrics side by side

Valuation

MetricARTVRLMD
P/B ratio1.021.69

Profitability

MetricARTVRLMD
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-26.14%-29.98%
ROIC-27.16%-30.78%

Growth (annualized)

MetricARTVRLMD
Total return CAGR (5Y)N/A-7.68%

Go deeper

Full ARTV analysisFull RLMD analysisInteractive comparison tool

Dig into the metrics

Artiva Biotherapeutics ROERelmada Therapeutics ROEArtiva Biotherapeutics operating marginRelmada Therapeutics operating marginArtiva Biotherapeutics revenue growthRelmada Therapeutics revenue growthArtiva Biotherapeutics free cash flowRelmada Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.